Evidence map›Paper›PMID 40604347›Full record

ReviewAlzheimer's & dementia : the journal of the Alzheimer's Association2025

Genetically determined Alzheimer's disease research advances: The Down Syndrome & Autosomal Dominant Alzheimer's Disease 2024 Conference.

Neus Falgàs, Lucia Maure-Blesa, Beau Ances, Lisi Flores-Aguilar, Sigan Hartley, Jason Hassenstab, M Florencia Iulita, Matthew Janicki, Katherine Koenig, Patrick Lao and 49 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

59 authors.

Neus FalgàsAlzheimer's Disease and Other Cognitive Disorders Unit, Service of Neurology, Hospital Clínic de Barcelona, Fundació de Recerca Clínic Barcelona-Institut d'Investigació Biomèdica August Pi i Sunyer, University of Barcelona, Barcelona, Spain.
Lucia Maure-BlesaMemory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Sant Antoni Maria Claret, Departamento de Medicina, Universitat Autónoma de Barcelona, Barcelona, Spain.ORCID 0000-0001-5643-7971
Beau AncesDepartment of Neurology, Washington University School of Medicine in St. Louis, St. Louis, Missouri, USA.
Lisi Flores-AguilarDepartment of Pathology and Laboratory Medicine, University of California, Irvine, California, USA.
Sigan HartleyWaisman Center, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Jason HassenstabDepartment of Neurology, Washington University School of Medicine in St. Louis, St. Louis, Missouri, USA.
M Florencia IulitaAltoida Inc., Washington, District of Columbia, USA.
Matthew JanickiDepartment of Disability and Human Development, University of Illinois Chicago, Chicago, Illinois, USA.
Katherine KoenigImaging Sciences, Imaging Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Patrick LaoGertrude H. Sergievsky Center and Taub Institute for Research on Alzheimer's Disease and the Aging Brain, College of Physicians and Surgeons, Columbia University, New York, New York, USA.
Johannes LevinDepartment of Neurology, Ludwig-Maximilians-University, Munich, Germany.
Eric McDadeDepartment of Neurology, Washington University School of Medicine in St. Louis, St. Louis, Missouri, USA.
Laurent MeijerPerha Pharmaceuticals; Centre de Perharidy, Hôtel de Recherche, Roscoff, France.
Michael S RafiiAlzheimer's Therapeutic Research Institute, USC Keck School of Medicine, San Diego, California, USA.
Heather M SnyderDivision of Medical and Scientific Relations, Alzheimer's Association, Chicago, Illinois, USA.
Raquel Sánchez-ValleAlzheimer's Disease and Other Cognitive Disorders Unit, Service of Neurology, Hospital Clínic de Barcelona, Fundació de Recerca Clínic Barcelona-Institut d'Investigació Biomèdica August Pi i Sunyer, University of Barcelona, Barcelona, Spain.
Juan ForteaMemory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Sant Antoni Maria Claret, Departamento de Medicina, Universitat Autónoma de Barcelona, Barcelona, Spain.
DSAD‐ADAD conference group
Jose Arriola InfanteMemory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Sant Antoni Maria Claret, Departamento de Medicina, Universitat Autónoma de Barcelona, Barcelona, Spain.
Mirea BalasaAlzheimer's Disease and Other Cognitive Disorders Unit, Service of Neurology, Hospital Clínic de Barcelona, Fundació de Recerca Clínic Barcelona-Institut d'Investigació Biomèdica August Pi i Sunyer, University of Barcelona, Barcelona, Spain.
Isabel BarroetaMemory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Sant Antoni Maria Claret, Departamento de Medicina, Universitat Autónoma de Barcelona, Barcelona, Spain.
Nicolas Barthelemy RDepartment of Neurology, Washington University School of Medicine in St. Louis, St. Louis, Missouri, USA.
Alexandre BejaninMemory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Sant Antoni Maria Claret, Departamento de Medicina, Universitat Autónoma de Barcelona, Barcelona, Spain.
Bessy BenejamBarcelona Down Medical Center, Fundació Catalana de Síndrome de Down, Entresòl, Barcelona, Spain.
Beatriz BoschAlzheimer's Disease and Other Cognitive Disorders Unit, Service of Neurology, Hospital Clínic de Barcelona, Fundació de Recerca Clínic Barcelona-Institut d'Investigació Biomèdica August Pi i Sunyer, University of Barcelona, Barcelona, Spain.
Angela BradshawAlzheimer Europe, Bertrange, Luxembourg.
Maria Carmona-IraguiMemory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Sant Antoni Maria Claret, Departamento de Medicina, Universitat Autónoma de Barcelona, Barcelona, Spain.
Ann CohenDepartment of Psychiatry, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Aina Comas AlbertíAlzheimer's Disease and Other Cognitive Disorders Unit, Service of Neurology, Hospital Clínic de Barcelona, Fundació de Recerca Clínic Barcelona-Institut d'Investigació Biomèdica August Pi i Sunyer, University of Barcelona, Barcelona, Spain.
Lajos CsincsikSchool of Medicine, Dentistry and Biomedical Science, Queen's University Belfast, University Rd, Belfast, UK.
A Claudio CuelloMcGill University Department of Pharmacology and Therapeutics, McGill University, Montreal, Quebec, Canada.
Laura Del Hoyo SorianoMemory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Sant Antoni Maria Claret, Departamento de Medicina, Universitat Autónoma de Barcelona, Barcelona, Spain.
Janna DijkstraGenomics of Neurodegenerative Diseases and Aging, Department of Human Genetics, Amsterdam University Medical Center, Amsterdam, Netherlands.
Natalie EdwardsGertrude H. Sergievsky Center and Taub Institute for Research on Alzheimer's Disease and the Aging Brain, College of Physicians and Surgeons, Columbia University, New York, New York, USA.
Sandra GiménezMemory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Sant Antoni Maria Claret, Departamento de Medicina, Universitat Autónoma de Barcelona, Barcelona, Spain.
Fernando Gonzalez-OrtizDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, University of Gothenburg, Gothenburg, Sweden.
Brian GordonDepartment of Neurology, Washington University School of Medicine in St. Louis, St. Louis, Missouri, USA.
Sara Gutiérrez FernándezVIB-KU Leuven Center for Brain & Disease Research, VIB Center for Brain & Disease research, Leuven, Belgium.
Benjamin HandenDepartment of Psychiatry, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Charlotte JacobLaboratory of Neurochemistry and Behaviour, Experimental Neurobiology Unit, University of Antwerp, Antwerpen, Belgium.
Erik JohnsonDepartment of Neurology, Emory University, Atlanta, Georgia, USA.
Charlotte JohanssonDivision of Neurogeriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Solna, Stockholm, Sweden.
Albert LladóAlzheimer's Disease and Other Cognitive Disorders Unit, Service of Neurology, Hospital Clínic de Barcelona, Fundació de Recerca Clínic Barcelona-Institut d'Investigació Biomèdica August Pi i Sunyer, University of Barcelona, Barcelona, Spain.
Alberto LleóMemory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Sant Antoni Maria Claret, Departamento de Medicina, Universitat Autónoma de Barcelona, Barcelona, Spain.
Samuel MorabitoDepartment of Pathology and Laboratory Medicine, University of California, Irvine, California, USA.
Alejandra O Morcillo-NietoMemory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Sant Antoni Maria Claret, Departamento de Medicina, Universitat Autónoma de Barcelona, Barcelona, Spain.
Laia Montoliu-GayaDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, University of Gothenburg, Gothenburg, Sweden.
Michael OkaforSorbonne Université, Institut du Cerveau-Paris Brain Institute - ICM, CNRS, APHP, Hôpital de La Pitié Salpêtrière, InsermParis, France Hôpital Pitié, Paris, France.
Agnes Pérez-MillanAlzheimer's Disease and Other Cognitive Disorders Unit, Service of Neurology, Hospital Clínic de Barcelona, Fundació de Recerca Clínic Barcelona-Institut d'Investigació Biomèdica August Pi i Sunyer, University of Barcelona, Barcelona, Spain.
Marie Claude PotierSorbonne Université, Institut du Cerveau-Paris Brain Institute - ICM, CNRS, APHP, Hôpital de La Pitié Salpêtrière, InsermParis, France Hôpital Pitié, Paris, France.
John RingmanDepartment of Neurology, University of Southern California, Los Angeles, California, USA.
Íñigo Rodríguez-BazMemory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Sant Antoni Maria Claret, Departamento de Medicina, Universitat Autónoma de Barcelona, Barcelona, Spain.
Eric RubensteinDepartment of Epidemiology, Boston University, Boston, Massachusetts, USA.
Natalie S RyanDementia Research Centre, Department of Neurodegenerative Diseases, UCL Queen Square Institute of Neurology, Queen Square, London, UK.
André StrydomInstitute of Psychiatry, Psychology, and Neuroscience, King's College London, Strand London, UK.
Lidia Vaqué-AlcázarMemory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Sant Antoni Maria Claret, Departamento de Medicina, Universitat Autónoma de Barcelona, Barcelona, Spain.
Lisa VermuntNeurochemistry Laboratory, Department of Laboratory Medicine, Amsterdam Neuroscience, VU University, Amsterdam UMC, Amsterdam, the Netherlands.
Laura Videla ToroMemory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Sant Antoni Maria Claret, Departamento de Medicina, Universitat Autónoma de Barcelona, Barcelona, Spain.
Shahid ZamanDepartment of Psychiatry, University of Cambridge, Cambridge, UK.

Funding

USCADRC Diversity Supplement PachicanoP30AG066530 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI HELENA Chang CHUI · 2020 to 2026
$27.8M
Agence Nationale de la Recherche DYRK-DOWNAgence Nationale de la Recherche (ANR), France 2030, Bpifrance, European Union's Horizon 2020 research and innovation program GO-DS21Alzheimer's Association AARG-22-923680Alzheimer's Association ISTAART Conference Support AwardEuropean Innovation Council (EIC), Accelerator Program 190138295Fondation Jérôme Lejeune 2326 - GRT-2024AFondos FEDERFundación Catalana del Síndrome de Down (FCSD)Fundación Pasqual MaragallGlobal Brain Health Institute GBHI_ALZ-18-543740Instituto de Salud Carlos III CD23/00235Instituto de Salud Carlos III CM21/00243Instituto de Salud Carlos III CM22/00052Instituto de Salud Carlos III CM22/00219Instituto de Salud Carlos III CM23/00291Instituto de Salud Carlos III CP20/00038Instituto de Salud Carlos III CP24/00112Instituto de Salud Carlos III JR22/00014Ministerio de Ciencias Innovación y UniversidadesNIA NIH HHS P30 AG066530UK Dementia Research InstituteUK Medical Research Council, UK NIHR UCLH Biomedical Research Centre, Dominantly Inherited Alzheimer Network
6 · The paper itself

Abstract

introductionThe Down syndrome-associated Alzheimer's disease (DSAD) autosomal dominant Alzheimer's disease (ADAD) 2024 Conference in Barcelona, convened under an Alzheimer's Association International Society to Advance Alzheimer's Research and Treatment (ISTAART) grant through the Down syndrome and Alzheimer's disease (AD) Professional Interest Area (PIA), brought together global researchers to foster collaboration and knowledge exchange between the fields of DSAD and ADAD.

methodsThis article provides a synthesis review of the conference proceedings, summarizing key discussions on biomarkers, natural history models, clinical trials, and ethical considerations in anti-amyloid therapies.

resultsA total of 211 attendees from 16 countries joined the meeting. Global researchers presented on disease mechanisms, therapeutic developments, and patient care strategies. Discussions focused on challenges and opportunities unique to DSAD and ADAD. Experts emphasized the urgent need for tailored clinical trials for ADAD and DSAD and debated the safety and efficacy of anti-amyloid treatments. Ethical considerations highlighted equitable access to therapies and the crucial role of patient and caregiver involvement. DISCUSSION: The conference highlighted the importance of inclusive research and collaboration across the genetic forms of AD. HIGHLIGHTS: Biomarker research and natural history models developed in Down syndrome-associated Alzheimer's disease (DSAD) and autosomal dominant Alzheimer's disease (ADAD) enable the prediction of disease progression not only for DSAD and ADAD, but also for sporadic Alzheimer's disease (AD). -Collaboration and knowledge exchange among researchers across these genetic forms of AD will accelerate our understanding of the pathophysiology and advance preventive trials in DSAD and ADAD. -Tailored clinical trials for DSAD are urgently needed to address specific safety and efficacy concerns. -Inclusive research practices are crucial for advancing treatments and understanding of DSAD and ADAD.

Indexed as

Alzheimer DiseaseBiomedical ResearchDown SyndromeBiomarkersCongresses as TopicHumansBiomarkersAutosomal dominant Alzheimer's diseaseBiomarkersClinical trialsDown syndromeNeuroimagingPathophysiology

Identifiers

PMID40604347
PMCPMC12221810

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.